The Pulmonary Fibrosis Foundations (PFF)’ Patient Registry is providing valuable data to support pulmonary fibrosis research, as evidenced by multiple presentations at the 2019 American Thoracic Society (ATS) conference, held May 17–22 in Dallas, Texas. The PFF Patient registry, launched in 2016, is a comprehensive collection of patient…
The first patient was dosed in a Phase 2b clinical trial investigating the safety and effectiveness of Respivant Biosciences’ inhalation therapy candidate RVT-1601 for idiopathic pulmonary fibrosis patients with persistent cough. Respivant Biosciences also has launched a new website — IPFcough.com — to increase awareness about the effects of cough…
High levels of nitric oxide in the lungs of people with idiopathic pulmonary fibrosis (IPF) are associated with faster disease progression and worse survival, researchers in Italy report. The findings were described in the study “Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic…
The Feldman Family Foundation is hosting a pulmonary fibrosis fund-raising event — its 6th Annual Texas Hold ‘Em Tournament and Casino Night — on Saturday (March 2), at the Chevy Chase Country Club in Wheeling, Illinois. The Feldman Family Foundation was founded in 2013 in honor of…
Lung cancer patients with underlying idiopathic pulmonary fibrosis (IPF) treated with proton radiation therapy live longer than those treated with X-ray irradiation, a study shows. Additionally, fewer occurrences of treatment-related lung complications were reported in proton therapy-treated patients. The study, “Preliminary result of definitive radiotherapy in patients with non-small cell…
Bridge Biotherapeutics’ investigational therapy candidate BBT-877 for idiopathic pulmonary fibrosis (IPF) has been awarded orphan drug designation by the U.S. Food and Drug Administration (FDA). According to the company, BBT-877 is a best-in-class autotaxin (ATX) inhibitor, and a potential anti-inflammatory and anti-fibrotic treatment for IPF. Studies have shown…
Promedior plans to begin Phase 3 testing of its investigational therapy PRM-151 for the treatment of idiopathic pulmonary fibrosis (IPF), now that the U.S. Food and Drug Administration has signed off on the trial design, the biotechnology company announced. The agreement was reached in an end-of-Phase-2 meeting between…
Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…
A mutation associated with the mucous-producing gene MUC5B, a known genetic risk factor for idiopathic pulmonary fibrosis (IPF), also is prevalent in rheumatoid arthritis patients with interstitial lung disease (ILD), according to a study led by researchers from the University of Colorado School of Medicine. The study, “MUC5B Promoter…
Studies supporting an investigational new drug (IND) application for X-165, a potential candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic disorders, have been completed, X-Rx recently announced. According to the U.S. Food and Drug Administration, an IND application permits the manufacturer to transport…
Get regular updates to your inbox.
